S. Wadler

发表

Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells.

S. Wadler, R. Horowitz, H. Y. Zhang, 1998, Biochemical pharmacology.

Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein.

C. Albanese, S. Wadler, R. Pestell, 2000, Molecular cell biology research communications : MCBRC.

The dl1520 Virus Is Found Preferentially in Tumor Tissue after Direct Intratumoral Injection in Oral Carcinoma

S. Wadler, M. Horwitz, H. Kaufman, 2005, Clinical Cancer Research.

Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects.

S. Wadler, E. Schwartz, R. Wersto, 1990, Cancer research.

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr

B N Bundy, M Markman, D. Alberts, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Perspectives for cancer therapies with cdk2 inhibitors.

S. Wadler, S Wadler, Scott Wadler, 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Long-term swallowing problems after organ preservation therapy with concomitant radiation therapy and intravenous hydroxyurea: initial results.

R. V. Smith, S. Wadler, J. Beitler, 2000, Archives of otolaryngology--head & neck surgery.

Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial.

G. Corner, L. Augenlicht, L. Augenlicht, 1997, Cancer research.

High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.

S. Groshen, H. Lenz, K. Danenberg, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants.

S. Wadler, M. Horwitz, A. Rozenblit, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

Sanjay Goel, Gary Goldberg, M. Einstein, 2005, Investigational New Drugs.

Antisense therapeutics in oncology: points to consider in their clinical evaluation.

S. Wadler, S. Mani, H. Fingert, 1999, Antisense & nucleic acid drug development.

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.

S. Wadler, E. Schwartz, L. Itri, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study.

M. Atkins, N. Petrelli, J. Kirkwood, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increasing the efficacy of 5-fluorouracil with interferons: preclinical, clinical, and pharmacokinetic studies.

J. Sparano, S. Wadler, 1993, Advances in experimental medicine and biology.

Combination therapy with 5-fluorouracil and IFN-alpha2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells.

S. Wadler, R. Horowitz, E. Schwartz, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

A. Benson, E. Vokes, S. Kornblau, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of cancer treatment-related diarrhea. Issues and therapeutic strategies.

A. Benson, E. Vokes, S. Kornblau, 2000, Journal of pain and symptom management.

J. Ajani, A. Benson, E. Vokes, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma.

S. Wadler, P. Wiernik, Wiernik Ph, 1990, Seminars in oncology.

Treatment of carcinoma of the esophagus with 5‐fluorouracil and recombinant alfa‐2a‐interferon

S. Wadler, A. Rozenblit, P. Wiernik, 1993, Cancer.

Biologic response modifiers in gynecologic malignancies.

S. Wadler, J. Dutcher, P. Wiernik, 1988, The Yale journal of biology and medicine.

Phase I-II study of 5-fluorouracil, recombinant interferon alpha2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus.

S. Wadler, J. Beitler, M. Camacho, 1999, American journal of clinical oncology.

Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.

J. Tepper, R. Goldberg, D. Ryan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.

E. Van Cutsem, S. Wadler, M. Rothenberg, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic treatment of advanced colorectal cancer: Incorporating new agents into the therapeutic strategy

S. Wadler, 2002 .

Phase I Clinical Trial of Irinotecan With Oral Capecitabine in Patients With Gastrointestinal and Other Solid Malignancies

S. Wadler, S. Mani, S. Goel, 2002, American journal of clinical oncology.

Mortality A ssociated W ith I rinotecan P lus B olus Fluorouracil/Leu covorin: S ummary F indings o f a n Independent P anel

S. Wadler, M. Rothenberg, N. Meropol, 2001 .

Phase II trial of N-(phosphonacetyl)-l-aspartate (PALA), 5-fluorouracil and recombinant interferon-α-2b in patients with advanced gastric carcinoma

E. Thiel, S. Wadler, E. Kreuser, 1996 .

Fulminant disseminated carcinomatosis arising from squamous cell carcinoma of the tongue.

H. Biller, S. Wadler, M. Spigelman, 1985, The American journal of medicine.

Diagnosis and Management of Cancer Treatment–Induced Diarrhea

S. Wadler, 2005 .

S. Wadler, V. Adams, T. Gatewood, 2009 .

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.

I. Hyodo, J. Abbruzzese, S. Wadler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.

N. Robert, J. Sparano, S. Wadler, 1993, Cancer research.

Cardiac abnormalities in patients with diffuse malignant pleural mesothelioma

S. Wadler, J. Holland, D. Mendelson, 1986, Cancer.

Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix.

C. Runowicz, S. Wadler, J. Beitler, 1996, Gynecologic oncology.

Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer

S. Wadler, J. Beitler, A. Rozenblit, 1995, Medical oncology.

Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors

John D. Roberts, A. Pavlick, S. Wadler, 2009, Cancer Chemotherapy and Pharmacology.

Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein.

S. Wadler, M. Schwartz, A. Siegel, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular targeting in pancreatic cancer.

S. Wadler, 2007, Reviews on recent clinical trials.

Carcinoma of the uterine cervix metastatic to behind the zygomatic arch: a case report.

S. Wadler, R. Mitnick, J. Challagalla, 1999, American journal of otolaryngology.

The role of anthracyclines in the treatment of gastric cancer.

S. Wadler, F. Muggia, M. Green, 1985, Cancer treatment reviews.

Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.

E. Plimack, C. Runowicz, S. Wadler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study.

S. Arbuck, H. Averette, S. Wadler, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.

D. Alberts, S. Wilczynski, S. Wadler, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined I ntraperitoneal a nd I ntravenous C hemotherapy f or Women W ith O ptimally D ebulked O varian C ancer: R esults From a n I ntergroup P hase I I T rial

D. Alberts, S. Wilczynski, S. Wadler, 2003 .

New developments in the treatment of ovarian cancer

S. Wadler, 2001, Expert opinion on investigational drugs.

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.

C. Runowicz, S. Wadler, H. Hochster, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer.

C. Runowicz, S. Wadler, H. Hochster, 1999, Gynecologic oncology.

Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer

M. Gonen, Helen X. Chen, N. Kemeny, 2005 .

A phase I trial of SR271425 given as a one hour infusion every 3 weeks to patients with advanced solid tumors

P. LoRusso, S. Wadler, M. Valdivieso, 2005 .

Effect of interferon on 5-fluorouracil-induced perturbations in pools of deoxynucleotide triphosphates and DNA strand breaks

S. Wadler, R. Horowitz, E. Schwartz, 1996, Cancer Chemotherapy and Pharmacology.

A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.

S. Wadler, F. Foss, H. Bailey, 2002, Gynecologic oncology.

Lack of Efficacy of Interferon-α Therapy in Recurrent, Advanced Cervical Cancer

D. Neuberg, R. Burk, C. Runowicz, 1995 .

Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.

S. Wadler, H. Hochster, M. Green, 1992, Journal of the National Cancer Institute.

Effects of a hybrid recombinant human alpha interferon (A/D) on in vitro cytotoxicity and in vivo localization of monoclonal antibody L6-cytosine deaminase conjugate in a colon cancer model.

S. Wadler, P. Senter, G. Anthony, 1998, Cancer biotherapy & radiopharmaceuticals.

Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer.

C. Runowicz, S. Wadler, H. Hochster, 1996, American journal of obstetrics and gynecology.

Mechanisms by which interferon potentiates chemotherapy.

S. Wadler, M. Hoffman, 1993, Cancer investigation.

Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells.

S. Wadler, E. Schwartz, M. Hoffman, 1992, Biochemical and biophysical research communications.

Phase I and II Agents in Cancer Therapy: I. Anthracyclines and Related Compounds

S. Wadler, P. Wiernik, J. Fuks, 1986, Journal of clinical pharmacology.

All‐trans retinoic acid and interferon‐α‐2a in patients with metastatic or recurrent carcinoma of the uterine cervix

S. Hallam, C. Runowicz, S. Wadler, 1997 .

All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.

S. Hallam, C. Runowicz, S. Wadler, 1997, Cancer.

Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea.

S. Wadler, P. Wiernik, H. Haynes, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors

S. Wadler, A. Kaubisch, A. Rozenblit, 2004, Cancer Chemotherapy and Pharmacology.

Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.

R. Ladner, S. Wadler, A. Murgo, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA).

M. Mazumdar, S. Wadler, J. Wright, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic analysis of proteasome-related pathways in patients with advanced gastric adenocarcinomas (AGA) treated on a phase II study with PS-341 (bortezomib) with or without irinotecan.

S. Wadler, J. Wright, A. Ocean, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93).

D. Cella, S. Wadler, C. Falkson, 2001, Cancer journal.

An ECOG Phase II Study of Amonafide in Unresectable or Recurrent Carcinoma of the Head and Neck (PB390)

D. Neuberg, S. Wadler, E. Schwartz, 2004, Investigational New Drugs.

Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.

S. Wadler, G. Soori, J. Schink, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma.

C. Runowicz, S. Wadler, L. Rodriguez-Rodriguez, 1989, Gynecologic oncology.

A REVIEW OF THE CLINICAL EXPERIENCE WITH IRINOTECAN (CPT‐11)

S. Wadler, R. Horowitz, P. Wiernik, 1997, American journal of therapeutics.

Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.

C. Runowicz, S. Wadler, A. Murgo, 2006, Gynecologic oncology.

Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days

S. Wadler, H. Hochster, F. Muggia, 2002, Anti-cancer drugs.

Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.

S. Wadler, E. Schwartz, 1990, Cancer research.

Antineoplastic activity of the combination of 5-fluorouracil and interferon: preclinical and clinical results.

S. Wadler, 1992, Seminars in oncology.

Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.

M. Sznol, S. Wadler, D. Makower, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biologic agents as biochemical modulators: pharmacologic basis for the interaction of cytotoxic chemotherapeutic drugs and interferon

S. Wadler, E. Schwartz, 2004, Cancer Chemotherapy and Pharmacology.

Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer.

C. Penning, Y. Humblet, X. Pivot, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of immunotherapy in colorectal cancer.

S. Wadler, 1991, Seminars in oncology.

Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.

S. Wadler, P. Wiernik, A. Lyver, 1990, Cancer research.

Renal Failure Related to Drugs and Disease

S. Wadler, J. Dutcher, 1987 .

Biochemical modulation of cytotoxic drugs by cytokines: molecular mechanisms in experimental oncology.

E. Thiel, S. Wadler, E. Kreuser, 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

High‐dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi‐institutional trial (radiation therapy oncology group protocol 8801)

S. Wadler, R. Byhardt, S. Order, 1992, Cancer.

SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells.

S. Wadler, B. Yu, M. Lane, 2002, Biochemical pharmacology.

Stage 4 squamous cell carcinoma of the tongue in a child: complete response to chemoradiotherapy.

R. V. Smith, S. Wadler, J. Beitler, 2001, Journal of pediatric hematology/oncology.

Phase II clinical trial of parenteral hydroxyurea and hyperfractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: Toxicity and efficacy with continuous ribonucleoside reductase inhibition

M. Mazumdar, S. Wadler, R. Owen, 2007, Head & neck.

Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase.

N. Baptiste, S. Wadler, E. Schwartz, 1994, Cancer research.

Partial reversal of doxorubicin resistance by forskolin and 1,9-dideoxyforskolin in murine sarcoma S180 variants.

S. Wadler, P. Wiernik, 1988, Cancer research.

Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation.

R. Diasio, J. Sparano, R. Zhang, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharyngeal transport dysfunction consequent to an organ-sparing protocol.

R. V. Smith, S. Wadler, J. Beitler, 1999, Archives of otolaryngology--head & neck surgery.

Decreased short- and long-term swallowing problems with altered radiotherapy dosing used in an organ-sparing protocol for advanced pharyngeal carcinoma.

S. Wadler, J. Beitler, Richard V. Smith, 2004, Archives of otolaryngology--head & neck surgery.

Close or positive margins after surgical resection for the head and neck cancer patient: the addition of brachytherapy improves local control.

R. V. Smith, B. Vikram, S. Wadler, 1998, International journal of radiation oncology, biology, physics.

Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.

S. Lipsitz, J. Kirkwood, A. Benson, 1996, American journal of clinical oncology.

A Pilot Study of Edrecolomab (Panorex, 17-1A Antibody) and Capecitabine in Patients with Advanced or Metastatic Adenocarcinoma

J. Sparano, S. Wadler, S. Mani, 2003, Cancer investigation.

PSC833: initial clinical results in refractory ovarian cancer patients.

P. Dottino, C. Runowicz, S. Wadler, 1998, Current opinion in oncology.

Measurement of deoxyuridine triphosphate and thymidine triphosphate in the extracts of thymidylate synthase-inhibited cells using a modified DNA polymerase assay.

R. Ladner, S. Wadler, R. Horowitz, 1997, Biochemical pharmacology.

Phase II study of sequential paclitaxel (P) and bryostatin-1 (Bryo) for patients with advanced pancreatic cancer (P 5624).

S. Wadler, S. Mani, H. Hochster, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modulation of 5-fluorouracil by interferon: a review of potential cellular targets

S. Wadler, R. Horowitz, E. Schwartz, 1995, Medical oncology.

Tumor-Associated Hypoglycemia

S. Wadler, 1987 .

Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution.

D. Neuberg, M. Atkins, S. Wadler, 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo.

P. Catalano, G. Corner, L. Augenlicht, 2001, Cancer research.

Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer

L. Tenteromano, J. Sparano, S. Wadler, 2004, Cancer Chemotherapy and Pharmacology.

Pelvic exenteration for cervix cancer: would additional intraoperative interstitial brachytherapy improve survival?

C. Runowicz, S. Wadler, J. Beitler, 1997, International journal of radiation oncology, biology, physics.

Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.

J. Hecht, A. Benson, A. Shields, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New barriers to ventricular invasion in paraglottic laryngeal cancer

B. Vikram, S. Wadler, P. Mahadevia, 1994, Cancer.

Histone acetylation and the cell-cycle in cancer.

S. Wadler, A. Senderowicz, S. Mani, 2001, Frontiers in bioscience : a journal and virtual library.

Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.

J. Manola, S. Arbuck, A. Benson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line.

M. Green, S. Wadler, F. Muggia, 1986, Cancer research.

Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo.

S. Wadler, E. Schwartz, D. Makower, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.

N. Baptiste, S. Wadler, E. Schwartz, 1995, Cancer research.

Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study.

C. Runowicz, S. Wadler, J. Beitler, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N-Methylformamide in Advanced Squamous Cancer of the Uterine Cervix: An Eastern Cooperative Oncology Group Phase II Trial

S. Wadler, D. Tormey, L. Rajdev, 2004, Investigational New Drugs.

Clinical toxicities of the combination of 5-fluorouracil and recombinant interferon alfa-2a: an unusual toxicity profile.

S. Wadler, P. Wiernik, A. Lyver, 1989, Oncology nursing forum.

Principles in the biomodulation of cytotoxic drugs by interferons.

S. Wadler, E. Schwartz, 1992, Seminars in oncology.

Interferon-induced acute renal failure: a case report and literature review

S. Wadler, R. Horowitz, D. Glicklich, 1995, Medical oncology.

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

이석호, 황수찬, T. Walsh, 2001, British Journal of Cancer.

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

S. Swain, C. Vogel, S. Wadler, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Krukenberg Tumors:Can Management Be Improved? 1

S. Wadler, K. O'Hanlan, R. Kaleya, 1999, Gynecologic and Obstetric Investigation.

Back to the future: new theories on 5-fluorouracil/interferon interactions.

S. Wadler, 1992, Cancer investigation.

A phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901.

J. Tepper, D. Ryan, D. Hollis, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S. Wadler, K. Hupart, S. Damle, 1999, The cancer journal from Scientific American.

A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas

C. Antonescu, R. Maki, G. Schwartz, 2005, Cancer.

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

M. Gonen, Helen X. Chen, N. Kemeny, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of initial therapy with melphalan versus cisplatin‐based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long term results—Eastern Cooperative Oncology Group study E2878

B. Yeap, S. Wadler, P. Carbone, 1996, Cancer.

Phase I I T rial o f I ntravenous C I-1042 i n P atients W ith Metastatic C olorectal C ancer

A. Shields, E. Galanis, J. Hecht, 2003 .

Advances in the treatment of metastatic colorectal cancer.

S. Wadler, S Wadler, A D Fishman, 2001, Clinical colorectal cancer.

Krukenberg tumors: can management be improved?

S. Wadler, K. O'Hanlan, R. Kaleya, 1999, Gynecologic and obstetric investigation.

Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.

C. Runowicz, S. Wadler, A. Murgo, 2004, Gynecologic oncology.

A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.

R. Burk, S. Wadler, C. Falkson, 2004, Gynecologic oncology.

Randomized Phase II Trial of Either Fluorouracil, Parenteral Hydroxyurea, Interferon‐αt‐2a, and Filgrastim or Doxorubicin/Docetaxel in Patients with Advanced Gastric Cancer with Quality‐of‐Life Assessment: Eastern Cooperative Oncology Group Study E6296

P. Catalano, D. Cella, A. Benson, 2002, Cancer journal.

The IFNs have been found to produce a large array of molecular and cellular actions of potential relevance to their use in cancer

S. Wadler, L. Schwartz, 2002 .

A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck

S. Wadler, J. Beitler, T. Kotz, 2004, Investigational New Drugs.

Adjuvant-like effects of lithium on peripheral blood mononuclear cells.

W. Borkowsky, S. Wadler, R. Holzman, 1980, Advances in experimental medicine and biology.

Chemo-embolization in the treatment of liver metastases from colorectal cancer.

S. Wadler, S. Cascinu, 1996, Cancer treatment reviews.

Phase II Trial of Etoposide, Doxorubicin (Adriamycin), and Cisplatin (EAP Regimen) in Advanced Gastric Cancer

J. Sparano, S. Wadler, E. Schwartz, 1990, American journal of clinical oncology.

Utility of embolization or chemoembolization as second‐line treatment in patients with advanced or recurrent colorectal carcinoma

S. Wadler, C. Bakal, P. Wiernik, 1994, Cancer.

Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy

S. Wadler, J. Kaplan, A. Einzig, 2004, Investigational New Drugs.

Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix.

B. Vikram, C. Runowicz, S. Wadler, 2002, International journal of radiation oncology, biology, physics.

Interferon augments the cytotoxicity of hydroxyurea without enhancing its activity against the M2 subunit of ribonucleotide reductase: effects in wild-type and resistant human colon cancer cells

S. Wadler, R. Horowitz, E. Schwartz, 1996, Cancer Chemotherapy and Pharmacology.

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III.

Mimi Y. Kim, M. Einstein, R. Burk, 2007, Gynecologic oncology.

Crescentic glomerulonephritis associated with prostatic carcinoma: evidence of immune-mediated glomerular injury.

S. Wadler, L. Sablay, R. Mennemeyer, 1990, The American journal of medicine.

Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.

S. Wadler, H. Kaufman, A. Rozenblit, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.

Mark O'Rourke, Joe Stephenson, Edward Chu, 2011, Clinical colorectal cancer.

Expression of retinoic acid receptor-beta 2 mRNA in normal cervical epithelium and cervical squamous cell carcinoma.

S. Hallam, C. Runowicz, S. Wadler, 1997, International journal of oncology.

Clinical Applications of P53-Directed Gene Therapy

S. Wadler, H. Kaufman, A. Rozenblit, 2002, I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.].

Molecular Targeting in Upper Gastrointestinal Malignancies

S. Wadler, 2008 .

Interferons as biochemical modulators.

E. Borden, S. Wadler, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II clinical trial with 5‐fluorouracil, recombinant interferon‐α‐2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus

S. Wadler, J. Beitler, P. Wiernik, 1996, Cancer.

A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.

G. Mcmahon, L. Sun, C. Liang, 2001, Cancer research.

Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver.

A. Negassa, S. Wadler, C. Bakal, 2002, Clinical colorectal cancer.

Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha.

S. Wadler, K. Hupart, T. Jones, 1998, Seminars in oncology.

Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma

C. Runowicz, S. Wadler, J. Beitler, 1995, The Journal of Laryngology & Otology.

Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the eastern cooperative oncology group (EST 2292)

D. Neuberg, A. Benson, S. Wadler, 1997, The cancer journal from Scientific American.

452 The oncolytic reovirus, Reolysin, augments the anticancer effects of cytotoxic agents in vitro against the ras-mutated human colon cancer cell line HCT116

M. Coffey, L. Klampfer, S. Shirasawa, 2004 .

Iodine-131 MIBG scintigraphy in small cell lung cancer

M. Blaufox, S. Rafii, S. Wadler, 2004, European Journal of Nuclear Medicine.

A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer

C. Cohen, C. Runowicz, S. Wadler, 1995 .

Bevacizumab in hepatocellular carcinoma (HCC) in patients without metastasis and without invasion of the portal vein

S. Wadler, M. Schwartz, D. Coll, 2005 .

Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein.

S. Wadler, D. Coll, J. Goldman, 2004, Journal of Clinical Oncology.

Thalidomide for advanced hepatocellular carcinoma

S. Wadler, 2005, Cancer.

Thymidine Phosphorylase Mediates the Sensitivity of Human Colon Carcinoma Cells to 5-Fluorouracil (*)

N. Baptiste, S. Wadler, E. Schwartz, 1995, The Journal of Biological Chemistry.

Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group.

C. Runowicz, S. Wadler, E. Schwartz, 1999, The cancer journal from Scientific American.

Colon Carcinoma Cells A Novel cdk 2-selective Inhibitor , SU 9516 , Induces Apoptosis in Updated

G. Mcmahon, C. Liang, S. Wadler, 2001 .

LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: Results of CALGB 80402

R. Goldberg, D. Niedzwiecki, S. Wadler, 2008 .

The role of interferons in the treatment of solid tumors.

S. Wadler, 1992, Cancer.

The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.

C. Runowicz, S. Wadler, J. Beitler, 1996, Seminars in oncology.

Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.

S. Wadler, D. Makower, 1999, Seminars in oncology.

Phase II Tria l o f Intravenous CI-1042 in Pat ients With Metastat ic Colorecta l Cancer

A. Benson, A. Shields, E. Galanis, 2003 .

Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2,-bis (3-5-dioxopiperazinyl-1-yl) propane (ICRF 187), on murine sarcoma S180 in vitro.

M. Green, S. Wadler, F. Muggia, 1987, Biochemical pharmacology.

Interferon‐mediated fatigue

S. Wadler, D. Makower, U. Malik, 2001, Cancer.

Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-α-2a in patients with advanced malignancies

S. Wadler, A. Rozenblit, R. Schechner, 1995, Investigational New Drugs.

Adjuvant effects of lithium chloride on human mononuclear cells in suppressor-enriched and suppressor-depleted systems.

W. Borkowsky, S. Wadler, B. Shopsin, 1981, Immunopharmacology.

Targeted therapy in colorectal cancer.

S. Wadler, 2007, Clinical colorectal cancer.

Newer Clinical Strategies for Combining Interferon and Cytotoxic Agents Against Solid Tumours and Hematological Malignancies

S. Wadler, 1994 .

D. Neuberg, M. Atkins, S. Wadler, 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer.

J. Dancey, C. Runowicz, S. Wadler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and II Agents in Cancer Therapy: Two Cisplatin Analogues and High‐Dose Cisplatin in Hypertonic Saline or With Thiosulfate Protection

S. Wadler, S Wadler, P. Wiernik, 1987, Journal of clinical pharmacology.

Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.

E. Plimack, C. Runowicz, S. Wadler, 2006, Gynecologic oncology.

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

John D. Roberts, C. Bloomfield, N. Christakis, 2005, Journal of the National Cancer Institute.